Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
6(38%)
Results Posted
50%(1 trials)
Terminated
2(13%)

Phase Distribution

Ph not_applicable
2
13%
Ph phase_2
4
25%
Ph phase_3
1
6%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

6

trials recruiting

Total Trials

16

all time

Status Distribution
Active(7)
Completed(2)
Terminated(2)
Other(5)

Detailed Status

Recruiting5
unknown5
Terminated2
Completed2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
6
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (57.1%)
Phase 31 (14.3%)
N/A2 (28.6%)

Trials by Status

not_yet_recruiting16%
recruiting531%
terminated213%
unknown531%
active_not_recruiting16%
completed213%

Recent Activity

6 active trials
Showing 5 of 16
active_not_recruitingphase_2

A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06490445
recruiting

Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)

NCT04526093
not_yet_recruitingphase_2

Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

NCT07374939
recruitingphase_2

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

NCT06605430
completed

Reactions of Older Adults Driving After Cannabis Exposure

NCT04629716
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06490445Phase 2

A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Active Not Recruiting
NCT04526093

Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)

Recruiting
NCT07374939Phase 2

Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Not Yet Recruiting
NCT06605430Phase 2

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

Recruiting
NCT04629716

Reactions of Older Adults Driving After Cannabis Exposure

Completed
NCT06206252

Can Medical Cannabis Affect Opioid Use?

Recruiting
NCT06518434Phase 2

A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients

Recruiting
NCT06217146Not Applicable

A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

Terminated
NCT05863910

Real World Evidence on the Use of Medical Cannabis in Pediatrics

Recruiting
NCT05578313

Inflammatory Bowel Diseases (IBD) Cannabis Registry

Unknown
NCT04376437Not Applicable

The Kinetics of Endocannabinoids in Patients With Chemotherapy Induced Peripheral Neuropathy by Using Medical Cannabis.

Unknown
NCT05115318

The Effect of Medical Cannabis on Tics, Premonitory Urge and Psychiatric Comorbidity in Adults With Tourette Syndrome

Completed
NCT05106504

Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease

Unknown
NCT03808935Phase 3

Cannabis Extract in Refractory Epilepsy Study

Terminated
NCT02523183

The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy

Unknown
NCT03859089

Cannabis for Opioid Substitution Trial

Unknown

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16